I-Mab Receives U.S. FDA IND Approval for Proprietary Anti-GM-CSF Monoclonal Antibody TJM2
- Sunday, December 23, 2018, 22:45
- Finance
- Add a comment
SHANGHAI, Dec. 23, 2018 /PRNewswire/ — I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, today announces that the US Food and Drug Administration (FDA) …
Source: https://www.prnewswire.com:443/news-releases/i-mab-receives-us-fda-ind-approval-for-proprietary-anti-gm-csf-monoclonal-antibody-tjm2-300770567.html
About the Author
adminasapcorp has written 39124 stories on this site.